FDA Final Guidance E8 (R1.) General considerations for clinical studies, April 2022. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e8r1-general-considerations-clinical-studies

FDA Final Guidance. Patient-focused drug development: collecting comprehensive and representative input. Revised on June 16th., 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-collecting-comprehensive-and-representative-input

Diversity and inclusion in clinical trials. National Institutes of Health (NIH) Policies. Retrieved April 11. 2024. https://nimhd.nih.gov/resources/understanding-health-disparities/diversity-and-inclusion-in-clinical-trials.html

FDA Guidance Draft for Industry. Diversity plans to improve enrollment of participants from underrepresented Racial and ethnic populations in clinical trials. 2022. https://www.regulations.gov/document/FDA-2021-D-0789-0002

FDA Guidelines Draft for Industry. Enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs. 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial

New benchmarks on protocol amendment practices, trends and their impact on clinical trial performance - Getz, K.; Smith, Z.; Botto, E. (Ther Innov Regul Sci, 2024)

New benchmarks characterizing growth in protocol design complexity - Getz, K. A.; Campo, R. A. (Ther Innov Regul Sci, 2018)

Malikova MA. Optimization of protocol design: a path to efficient, lower cost clinical trial execution. Future Sci OA. 2016;2(1). https://doi.org/10.4155/fso.15.89.

Impact of protocol deviations on the clinical study - Chodankar, D. (Perspect Clin Res, 2023)

Differential dropout and bias in randomised controlled trials: when it matters and when it May not - Bell, M. L.; Kenward, M. G.; Fairclough, D. L.; Horton, N. J. (BMJ, 2013)

Risk-based quality and compliance management in clinical trials with combination products in changing global regulatory environment - Kaliaev, A. O.; Malikova, M. A. (Ther Innov Regul Sci, 2020)

etc. Regulatory perspectives of combination products - Tian, J.; Song, X.; Wang, Y.; Cheng, M.; Lu, S. (Bioact Mater, 2021)

User’s guide to correlation coefficients - Akoglu, H. (Turk J Emerg Med, 2018)

US Census Bureau Income by Zip Code. Income by zip code—Census bureau search. (n.d). Retrieved September 25, 2024. https://data.census.gov/all?q=income%20by%20zip%20code

Calculate Your BMI - Standard BMI Calculator. National Heart Lung and Blood Institute, U.S. Department of Health and, Services H. Sept., www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm. Accessed 30 2024.

Optimization of protocol design: a path to efficient, lower cost clinical trial execution - Malikova, M. A. (Future Sci OA, 2016)

Daniel W. W. Kendall’s tau. Applied Nonparametric Statistics. 2nd Edition. Boston: PWS-Kent. 1990; 365–377. ISBN 978-0-534-91976-4.

FDA Guidance for Industry E3 Structure and Content of Clinical Study Reports Questions and Answers (R1). January, 2013. https://www.fda.gov/media/84857/download

Protocol deviations: A holistic approach from defining to reporting - Galuchie, L.; Stewart, C.; Meloni, F. (Ther Innov Regul Sci, 2021)